Aglaia BioMedical Ventures

About The Fund

Aglaia BioMedical Ventures, also known as Aglaia Oncology Funds, is an investment firm that specializes in the oncology sector with a focus on financing and developing early-stage breakthroughs in cancer treatment. Founded in 2004, Aglaia brings decades of expert experience in cancer research and oncology drug development. They have established an exceptional reputation for initiating biotech companies geared towards oncology drug development and offering strategic direction in collaboration with innovators and entrepreneurs. The team's comprehensive experience spans designing research and development plans from initial screening to clinical studies. Aglaia has launched multiple Oncology Funds, namely Aglaia Oncology Funds I (which is dissolved) and II, Aglaia Oncology Growth Opportunity Fund, and its sequel, all of which are active, alongside a planned Fund III. These funds have participated in the inception of 12 early-stage companies, half of which were founded by Aglaia themselves. Through strategic and operational involvement, the team has notably enhanced the transition of portfolio companies from early-stage to clinical-stage, de-risking and maturing them into appealing opportunities for licensing, acquisition, or initial public offerings. Aglaia specifically targets early-stage oncology drug development, disruptive science with transformative potential for cancer diagnosis and therapy, and a diversity of drug modalities and development phases. They mandate robust preclinical validation and patentability of the inventions they invest in. With an investment sweet spot of $1,500,000, their range goes from a minimum of $100,000 to a maximum of $5,000,000, primarily in seed and Series A rounds. Aglaia's approach combines oncological focus with disciplined financing and hands-on management to emphasize value creation and capital efficiency, principles they consider essential for early-stage ventures' success. Furthermore, the firm has created a Life Sciences Impact Suite in collaboration with Sinzer (now part of Grant Thornton) to measure the socio-economic impact of their investments. Dedicated to cancer treatment advancements, Aglaia derives its name from the Greek goddess of beauty and good health and strives to reflect her virtues by fostering wellbeing through innovative cancer therapies.